GO:0004653 polypeptide N-acetylgalactosaminyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004653 describes the enzymatic activity that transfers N-acetyl-D-galactosamine (GalNAc) from UDP-GalNAc to serine or threonine residues of polypeptides, initiating mucin-type O-glycosylation.
• This activity is carried out by a large family of polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts), encoded by GALNT genes, which share a conserved catalytic domain but differ in substrate specificity and tissue distribution.
• GalNAc-Ts are type II membrane proteins localized mainly in the Golgi apparatus, where they act in a coordinated manner to generate the O-glycan core structures.
• Dysregulation of GalNAc-T activity is linked to cancer progression, metabolic disorders, and immune evasion, making these enzymes attractive therapeutic targets.
• Studying GO:0004653 requires a combination of biochemical assays, CRISPR-based gene editing, and glycoproteomics to dissect isoenzyme-specific functions.
• EDITGENE provides custom CRISPR services, including knockout, point mutation, knock-in, and overexpression models, to accelerate research on GalNAc-T biology and O-glycosylation.
Description
Polypeptide N-acetylgalactosaminyltransferase activity (GO:0004653) is the enzymatic function responsible for the first committed step in mucin-type O-glycosylation, a widespread post-translational modification that decorates serine and threonine residues of secreted and membrane proteins with N-acetylgalactosamine (GalNAc). This reaction is catalyzed by a family of enzymes known as GalNAc-Ts, which transfer GalNAc from the donor substrate UDP-GalNAc to the hydroxyl group of acceptor amino acids, thereby initiating the assembly of complex O-glycan structures. The resulting O-glycans play critical roles in protein stability, cell signaling, and immune recognition, and their aberrant expression is a hallmark of various diseases, including cancer and metabolic disorders. Researchers are particularly interested in GO:0004653 because it represents a nodal point for understanding how cells regulate the O-glycoproteome. The human genome encodes up to 20 GALNT genes, each with distinct but overlapping substrate specificities, enabling fine-tuned regulation of glycosylation in different tissues and physiological contexts. For example, GALNT15 has been shown to regulate adipogenesis in human SGBS cells, while GALNT2 in ventromedial hypothalamus neurons controls systemic glucose homeostasis through a brain-liver neurocircuit. Moreover, GalNAc-T18 (GALNT18) can non-catalytically modulate ER homeostasis and O-glycosylation, highlighting additional layers of regulation beyond catalysis. Given the broad impact of O-glycosylation on health and disease, tools to precisely manipulate GALNT genes are essential. This article provides a comprehensive overview of GO:0004653, covering its definition, molecular mechanism, key genes, disease associations, and state-of-the-art research methods, including CRISPR-based approaches for functional studies.
polypeptide N-acetylgalactosaminyltransferase activity At A Glance
| GO ID | GO:0004653 |
|---|---|
| GO term | polypeptide N-acetylgalactosaminyltransferase activity |
| Ontology | molecular_function |
| Synonym | UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase activity; glycoprotein acetylgalactosaminyltransferase activity; protein-UDP acetylgalactosaminyltransferase activity |
| Major function | Initiates mucin-type O-glycosylation by transferring GalNAc to serine/threonine residues of polypeptides |
| Reaction | UDP-N-acetyl-D-galactosamine + polypeptide = UDP + N-acetyl-D-galactosaminyl-polypeptide |
| Localization | Golgi apparatus (type II membrane proteins) |
| Enzyme family | GalNAc-T family (encoded by GALNT genes) |
| Substrates | UDP-GalNAc (donor); polypeptide with serine/threonine (acceptor) |
What Is GO:0004653?
GO:0004653, polypeptide N-acetylgalactosaminyltransferase activity, is defined as the catalysis of the reaction: UDP-N-acetyl-D-galactosamine + polypeptide = UDP + N-acetyl-D-galactosaminyl-polypeptide. This reaction modifies serine or threonine residues in polypeptide chains by transferring N-acetylgalactosamine from UDP-N-acetylgalactosamine to the hydroxyl group of the amino acid, and it constitutes the first step in O-glycan biosynthesis.
Why Is polypeptide N-acetylgalactosaminyltransferase activity Important in Cell Biology?
GO:0004653 is fundamental to understanding mucin-type O-glycosylation, a post-translational modification that affects a vast array of proteins involved in cell adhesion, signaling, and immune response. Dysregulation of this activity has been implicated in numerous human diseases, including cancer, where altered O-glycosylation can promote tumor progression and immune evasion. For instance, GALNT16-mediated glycosylation of PD-L1 contributes to anti-PD-1 resistance in hepatocellular carcinoma. Additionally, GalNAc-T2 in hypothalamic neurons regulates glucose counterregulation, linking O-glycosylation to metabolic control. Thus, studying this activity provides insights into basic cell biology and offers potential therapeutic targets.
• Initiates O-glycan biosynthesis, a key post-translational modification affecting protein function and stability.
• Plays a role in adipogenesis, as GALNT15 regulates differentiation of human SGBS adipocytes.
• Modulates systemic glucose homeostasis via GALNT2 in ventromedial hypothalamus neurons.
• Contributes to cancer immune evasion through GalNAc-T16-mediated PD-L1 glycosylation.
• GalNAc-T18 non-catalytically regulates ER homeostasis and O-glycosylation, expanding its functional repertoire.
• Isozyme-specific surface charge governs substrate preferences, affecting mucin-type O-glycosylation patterns.
• Structural studies of GalNAc-T7 provide a basis for understanding catalytic mechanisms and designing inhibitors.
• Alterations in GalNAc-T activity are associated with developmental defects and diseases such as cancer and metabolic disorders.
• Enables the study of O-glycoproteome dynamics in health and disease.
• Provides a target for CRISPR-based functional genomics and therapeutic intervention.
Molecular Mechanism of polypeptide N-acetylgalactosaminyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme first grabs the sugar donor and the target protein.
GalNAc-Ts recognize specific serine or threonine residues in acceptor polypeptides, often in the context of proline-rich sequences. The enzyme binds the donor substrate UDP-GalNAc and the acceptor polypeptide in a sequential ordered mechanism. Structural studies of GalNAc-T7 have revealed key residues involved in substrate binding and catalysis. Isozyme-specific surface charge properties influence substrate preferences, as shown for GalNAc-T isozymes.
Catalytic Transfer of GalNAc
In simple terms: The enzyme snips off GalNAc from UDP and attaches it to the protein.
The catalytic domain of GalNAc-Ts catalyzes the transfer of N-acetylgalactosamine from UDP-GalNAc to the hydroxyl group of serine or threonine, forming an alpha-O-glycosidic linkage. This reaction releases UDP and generates the Tn antigen (GalNAc-alpha-O-Ser/Thr), the simplest O-glycan. The reaction is the first step in O-glycan biosynthesis.
Isozyme-Specific Functions and Regulation
In simple terms: Different versions of the enzyme do slightly different jobs.
The human GALNT gene family comprises up to 20 members, each with distinct tissue expression and substrate specificity. For example, GALNT15 regulates adipogenesis, while GALNT2 in hypothalamic neurons controls glucose homeostasis. GALNT18 can non-catalytically regulate ER homeostasis and O-glycosylation. Surface charge of GalNAc-T isozymes modulates substrate preferences, affecting mucin-type O-glycosylation.
Cofactors and Localization
In simple terms: The enzyme needs to be in the right place and may require helper molecules.
GalNAc-Ts are type II membrane proteins localized to the Golgi apparatus, where they act in the secretory pathway. They require divalent metal ions (typically Mn2+) for catalysis. The luminal regions of GALNT18 interact with ER resident proteins UGGT1, PLOD3, and LPCAT1, which may regulate its retention and activity.
Key Genes Involved in GO:0004653 polypeptide N-acetylgalactosaminyltransferase activity
The following genes encode enzymes with polypeptide N-acetylgalactosaminyltransferase activity (GO:0004653) or are directly involved in its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALNT1 | Initiates O-glycosylation of many proteins | Widely expressed; model for studying O-glycan biosynthesis |
| GALNT2 | Regulates glucose homeostasis in hypothalamic neurons | Linked to metabolic disorders; brain-liver neurocircuit |
| GALNT3 | O-glycosylates FGF23, regulating phosphate homeostasis | Mutations cause familial tumoral calcinosis |
| GALNT7 | Structural basis of carbohydrate transfer activity | Provides insights into catalytic mechanism |
| GALNT15 | Regulates adipogenesis in human SGBS cells | Potential target for obesity research |
| GALNT16 | Glycosylates PD-L1, promoting immune evasion | Implicated in anti-PD-1 resistance in HCC |
| GALNT18 | Non-catalytically regulates ER homeostasis and O-glycosylation | Interacts with ER resident proteins |
| GALNT5 | O-glycosylates mucins and other proteins | Associated with cancer progression |
| GALNT6 | Involved in O-glycosylation of MUC1 | Role in tumorigenesis |
| GALNT10 | O-glycosylates proteins in secretory pathway | Potential biomarker in cancer |
| GALNT11 | Regulates O-glycosylation of Notch receptors | Implicated in developmental signaling |
| GALNT12 | O-glycosylates intestinal mucins | Associated with colorectal cancer |
| GALNT13 | Neuronal O-glycosylation | Role in nervous system function |
| GALNT14 | O-glycosylates death receptors | Modulates apoptosis sensitivity |
| GALNT17 | O-glycosylates proteins in brain | Linked to neurodevelopmental disorders |
| GALNT19 | O-glycosylates proteins in immune cells | Potential role in immune regulation |
| GALNT20 | O-glycosylates proteins in testis | Tissue-specific functions |
| GALNT8 | O-glycosylates proteins in respiratory epithelium | Studied in tracheal epithelial microsomes |
How Is polypeptide N-acetylgalactosaminyltransferase activity Regulated?
The activity of polypeptide N-acetylgalactosaminyltransferases is regulated at multiple levels. Transcriptional control of GALNT genes varies by tissue and developmental stage. For example, GALNT15 expression is modulated during adipogenesis. Post-translational regulation includes interactions with ER resident proteins; GALNT18 retention in the ER depends on its luminal regions interacting with UGGT1, PLOD3, and LPCAT1. Additionally, the surface charge of GalNAc-T isozymes governs substrate preferences, providing a mechanism for fine-tuning O-glycosylation. Metabolic signals, such as glucose levels, can influence GALNT2 function in hypothalamic neurons. Furthermore, GalNAc-T16-mediated glycosylation of PD-L1 is regulated in the context of cancer immune evasion.
polypeptide N-acetylgalactosaminyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALNT16 | Hepatocellular carcinoma, anti-PD-1 resistance | KO and overexpression in HCC cell lines; mouse xenografts |
| GALNT2 | Hypoglycemia counterregulation, metabolic disorders | Neuron-specific KO mice; hypothalamic cell lines |
| GALNT15 | Adipogenesis, obesity | Human SGBS cells with KO/overexpression |
| GALNT18 | ER homeostasis, O-glycosylation | KO and tagged knock-in in HEK293 or HeLa cells |
| GALNT7 | Catalytic mechanism, O-glycosylation | Recombinant protein expression and structural studies |
Cancer and Immune Evasion
Altered O-glycosylation is a hallmark of cancer. GALNT16-mediated glycosylation of PD-L1 promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma, highlighting the role of GalNAc-T activity in immune checkpoint regulation. Other GALNTs, such as GALNT6 and GALNT12, are implicated in tumorigenesis and colorectal cancer, respectively. The Tn antigen, a product of GO:0004653, is often exposed on tumor cells and is associated with poor prognosis.
Metabolic Disorders
GALNT2 in ventromedial hypothalamus neurons counterregulates hypoglycemia via a brain-liver neurocircuit, linking O-glycosylation to systemic glucose homeostasis. GALNT15 regulates adipogenesis in human SGBS cells, suggesting a role in obesity and metabolic syndrome. These findings indicate that GalNAc-T activity is critical for metabolic regulation.
ER Homeostasis and Protein Folding
GALNT18 non-catalytically regulates ER homeostasis and O-glycosylation, and its retention in the ER depends on interactions with UGGT1, PLOD3, and LPCAT1. Dysregulation of this process may contribute to ER stress-related diseases, including neurodegeneration and diabetes.
From polypeptide N-acetylgalactosaminyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of GALNT15 loss on adipogenesis? | GALNT15 knockout in human SGBS cells |
| How does GALNT2 in VMH neurons regulate glucose? | Neuron-specific GALNT2 knockout mice |
| Does GALNT16-mediated PD-L1 glycosylation affect immunotherapy? | GALNT16 knockout in HCC cells; PD-1 blockade assays |
| How does GALNT18 regulate ER homeostasis? | GALNT18 knockout and point mutants in HEK293 cells |
| What is the substrate specificity of GalNAc-T7? | Recombinant GalNAc-T7 with point mutations in catalytic domain |
| How does surface charge affect GalNAc-T isozyme function? | Charge-swap mutants of GalNAc-Ts expressed in cells |
How to Study the polypeptide N-acetylgalactosaminyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro transferase assay | Enzymatic activity using peptide substrates | Kinetic characterization of GalNAc-Ts |
| Glycoproteomics (LC-MS/MS) | O-glycosylation sites and structures | Global O-glycoproteome profiling |
| CRISPR knockout | Loss-of-function phenotypes | Studying GALNT15 in adipogenesis |
| CRISPR point mutation | Specific catalytic residue function | Dissecting GalNAc-T7 mechanism |
| Knock-in of tags | Localization and interactions | GALNT18 ER retention studies |
| Overexpression | Gain-of-function effects | GALNT16-mediated PD-L1 glycosylation |
| Co-immunoprecipitation | Protein-protein interactions | GALNT18 interactions with UGGT1, PLOD3, LPCAT1 |
| Animal models (conditional KO) | In vivo function | GALNT2 in glucose homeostasis |
Biochemical Assays for GalNAc-T Activity
In vitro assays using synthetic peptides and UDP-GalNAc can measure transferase activity. For example, tracheal epithelial microsomes were used to detect polypeptide N-acetylgalactosaminyltransferase activity. Recombinant enzymes can be produced for kinetic studies.
Glycoproteomics and Mass Spectrometry
Mass spectrometry-based glycoproteomics enables global mapping of O-glycosylation sites and structures. This approach can identify changes in O-glycan occupancy upon modulation of GALNT genes.
CRISPR-Cas9 Gene Editing
CRISPR knockout, point mutation, and knock-in models allow precise dissection of GALNT gene function. For instance, GALNT15 knockout in SGBS cells revealed its role in adipogenesis. Neuron-specific GALNT2 knockout mice were used to study glucose regulation.
Imaging and Subcellular Localization
Fluorescence microscopy of tagged GalNAc-Ts can reveal their Golgi or ER localization. GALNT18 retention in the ER was demonstrated using tagged constructs and interaction studies.
How CRISPR Can Be Used to Study GO:0004653 polypeptide N-acetylgalactosaminyltransferase activity
Knockout
CRISPR knockout of GALNT genes is used to eliminate enzyme activity and study loss-of-function phenotypes. For example, GALNT15 knockout in human SGBS cells demonstrated its role in adipogenesis. Neuron-specific GALNT2 knockout mice revealed its function in glucose counterregulation.
Point Mutation
Point mutations in the catalytic domain of GalNAc-Ts can abolish enzymatic activity while preserving protein structure, allowing separation of catalytic and non-catalytic functions. This approach was used to study GalNAc-T7 structure-function relationships.
Knock-in
Knock-in of epitope tags or fluorescent proteins enables visualization and interaction studies. Tagged GALNT18 was used to show ER retention dependent on luminal regions. Knock-in of disease-associated mutations can model human disorders.
Overexpression
Overexpression of GALNT genes can mimic gain-of-function states observed in cancer. For instance, GALNT16 overexpression promoted PD-L1 glycosylation and anti-PD-1 resistance in HCC cells.
How EDITGENE Supports polypeptide N-acetylgalactosaminyltransferase activity Research
Researchers studying polypeptide N-acetylgalactosaminyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in O-glycosylation, metabolic regulation, or cancer progression. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell and animal models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for polypeptide N-acetylgalactosaminyltransferase activity research.
Frequently Asked Questions About polypeptide N-acetylgalactosaminyltransferase activity
What is polypeptide N-acetylgalactosaminyltransferase activity?
It is the enzymatic activity (GO:0004653) that transfers N-acetylgalactosamine from UDP-GalNAc to serine or threonine residues of proteins, initiating O-glycan biosynthesis.
What genes are involved in polypeptide N-acetylgalactosaminyltransferase activity?
The human GALNT gene family, including GALNT1, GALNT2, GALNT3, GALNT7, GALNT15, GALNT16, and GALNT18, among others.
What is the role of GALNT15 in adipogenesis?
GALNT15 regulates adipogenesis in human SGBS cells, as shown by knockout studies.
How does GALNT2 affect glucose homeostasis?
GALNT2 in ventromedial hypothalamus neurons counterregulates hypoglycemia via a brain-liver neurocircuit.
What is the link between GALNT16 and cancer immunotherapy?
GALNT16-mediated glycosylation of PD-L1 promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma.
How does GALNT18 regulate ER homeostasis?
GALNT18 non-catalytically regulates ER homeostasis and O-glycosylation, and its ER retention depends on interactions with UGGT1, PLOD3, and LPCAT1.
What is the structural basis of GalNAc-T7 activity?
Structural studies of GalNAc-T7 have revealed key residues involved in carbohydrate transfer.
How can I study polypeptide N-acetylgalactosaminyltransferase activity?
Use biochemical assays, glycoproteomics, CRISPR knockout/knock-in, and overexpression models.
What diseases are associated with altered GalNAc-T activity?
Cancer, metabolic disorders, and ER stress-related diseases.
What services does EDITGENE offer for GalNAc-T research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
Polypeptide N-acetylgalactosaminyltransferase activity (GO:0004653) is a cornerstone of mucin-type O-glycosylation, with far-reaching implications for protein function, cell signaling, and human disease. The GALNT gene family encodes a diverse set of enzymes that fine-tune O-glycan structures in a tissue-specific manner, and their dysregulation contributes to cancer, metabolic disorders, and ER stress. Advances in CRISPR-based gene editing and glycoproteomics are accelerating our understanding of these enzymes. EDITGENE stands ready to support your research with tailored CRISPR models and bioinformatics solutions.
References
- 1. Takahashi A et al.. 2024. Polypeptide N-acetylgalactosaminyltransferase-15 regulates adipogenesis in human SGBS cells.. Sci Rep 14(1):20049 PMID: 39209927
- 2. Ballard CJ et al.. 2023. Polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) isozyme surface charge governs charge substrate preferences to modulate mucin type O-glycosylation.. Glycobiology 33(10):817-836 PMID: 37555669
- 3. Shan A et al.. 2019. Polypeptide N-acetylgalactosaminyltransferase 18 non-catalytically regulates the ER homeostasis and O-glycosylation.. Biochim Biophys Acta Gen Subj 1863(5):870-882 PMID: 30797803
- 4. Wang J et al.. 2025. Galnt2 neurons in the ventromedial hypothalamus counterregulate hypoglycemia via a brain-liver neurocircuit.. Cell Metab 37(11):2264-2279.e10 PMID: 41092902
- 5. Lin SS et al.. 2025. Yin Yang 1 Promotes Antiprogrammed Cell Death-1 Resistance in Hepatocellular Carcinoma through Polypeptide N-Acetylgalactosaminyltransferase 16-Mediated Glycosylation of Programmed Death Ligand-1.. MedComm (2020) 6(12):e70504 PMID: 41322030
- 6. Cottrell JM et al.. 1992. Polypeptide N-acetylgalactosaminyltransferase activity in tracheal epithelial microsomes.. Biochem J 283 ( Pt 1)(Pt 1):299-305 PMID: 1373603
- 7. Jia W et al.. 2021. Polypeptide N-acetylgalactosaminyltransferase 18 retains in endoplasmic reticulum depending on its luminal regions interacting with ER resident UGGT1, PLOD3 and LPCAT1.. Glycobiology 31(8):947-958 PMID: 33909026
- 8. Yu C et al.. 2019. Structural basis of carbohydrate transfer activity of UDP-GalNAc: Polypeptide N-acetylgalactosaminyltransferase 7.. Biochem Biophys Res Commun 510(2):266-271 PMID: 30685086
